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EXTENSIVE EVALUATION OF GENETIC POLYMORPHISM
OF CYP2C19 IN A KOREAN POPULATION: INTERETHNIC
COMPARISON AMONG ASIAN POPULATIONS. J. Lee, BS, Y.
Yoon, MD, PhD, H. Jeong, MS, S. Lee, PhD, K. Liu, PhD, W. Kang,
PhD, I. Cha, MD, PhD, J. Shin, MD, PhD, Inje University, Busan,
Republic of Korea.
We evaluated the frequency distribution of the cytochrome P450
2C19 (CYP2C19) allelic variants in a Korean population and also
measured the metabolic ratio of omeprazole, a probe drug for
CYP2C19 according to the genotypes. The results were compared
with those of other ethnics including Vietnamese data which we had
studied. Genotyping of CYP2C19 (*2 and *3) was carried out in 282
Korean subjects using PCR-RFLP and ninety-four subjects were
participated in phenotyping study using omeprazole. Plasma concen-
trations of omeprazole and its metabolite, hydroxy-omeprazole were
measured at 2hr after 20mg omeprazole intake. Forty subjects were
identified to have CYP2C19 genotype of PM with the frequency of
8.9% CYP2C19*2/*2, 3.9% CYP2C192/*3, and 1.4% CYP2C19*3/
*3, while 242 Korean subjects carried extensive metabolizer (EM)
genotypes which consists of CYP2C19*1/*1 (41.8%),
CYP2C19*1/*2 (35.5%), and CYP2C19*1/*3 (8.5%). The frequency
distribution of metabolic ratio was distinctly bimodal. Ten Korean
subjects were identified to be PMs with an antimode of 1.2. The
frequency (12.6 %) of PM in Korean population is significantly
higher than those in Vietnamese (7.1 %) and Thai (6.5), but lower
than those in Chinese (19.8 %), Filipinos (22.6 %) and Japanese
(18.8%).
PII-63
WHEN SHOULD URINE SAMPLES FOR NAT2 PHENOTYP-
ING WITH CAFFEINE BE COLLECTED? A. Jetter, MD, M.
Kinzig-Schippers, PhD, M. Illauer, BSc., D. Tomalik-Scharte, BSc.,
F. Sörgel, PhD, U. Fuhr, MD, University of Cologne, Institute for
Biomedical and Pharmaceutical Research, Cologne, Germany.
For N-acetyltransferase type 2 (NAT2) phenotyping, urinary ratios
of caffeine metabolites are determined after a caffeine test dose. It is
not known how these ratios change with postdose time, and which
urine collection interval is best for phenotyping.
Therefore, 16 healthy male Caucasians collected urine before and
0-2, 2-4, 4-6, 6-8, 8-12, 12-16, and 16-24 h after a 150 mg caf-
feine test dose. The test was repeated after 10 days. Concentrations
of 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 5-
acetylamino-6-amino-3-methyluracil (AAMU), 1-methylxanthine
(1X) and 1-methylurate (1U) were measured with LC-MS/MS (LOQ,
100 ng/mL). As a NAT2 metric, the molar ratio (AFMUAAMU)/
(1X1UAFMUAAMU) was determined.
In both periods, urinary ratios were stable from 4 until 24 hours
postdose. The arithmetic means for the collection periods ranged
from 0.152 to 0.169 and from 0.163 and 0.186, respectively, the CV
was 6 % in all cases. Intraindividual CVs were between 9 and 16
% starting 4 hours postdose, while interindividual variability reached
values between 58 and 66 %, respectively. There was no statistically
significant difference in CV between the respective collection periods
or between study periods. Hence, urine for NAT2 phenotyping may
be collected at any time between 4 and 24 hours after caffeine dosing.
The low intraindividual CVs enable the conductance of interaction
studies assessing the effect of drugs on NAT2 activity with a sample
size as low as n12 subjects.
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TISSUE BIOPSY TECHNIQUES FOR GENE-EXPRESSION
PROFILING IN CLINICAL PHARMACOLOGY. M. van Doorn,
MD, M. Kemme, MD, PhD, A. Cohen, MD, PhD, E. van Hoogdalem,
PhD, K. Burggraaf, MD, PhD, Centre for Human Drug Research,
Leiden, Netherlands.
Gene-expression profiling studies require sufficient quality/quan-
tity mRNA to obtain valid results. In animal studies, obtaining
relevant tissue material is not a problem, but in humans there are
obvious constraints. Therefore, we evalauted tissue biopsy tech-
niques, perceived burden and the RNA extraction methods in 12
healthy subjects.
On a single day a muscle and fat biopsy were done and a 10ml
blood sample was taken, followed by follow-up visits after 3 and 7
days. Abdominal sc adipose tissue was sampled with a suction
technique after local anaesthesia. Muscle tissue was sampled with a
modified Bergström needle from the quadriceps muscle under sterile
conditions and local anaesthesia. Tolerability was assessed with
questionnaires directly after the procedure and at follow-up visits.
The procedures were well tolerated by all subjects. The fat biospy
was associated with none to minimal discomfort both during the
procedure and during follow-up. The discomfort of the muscle biopsy
was rated as comparable to the venepuncture. At follow-up a mild
bruise-like feeling for a median time of 48 hrs was reported.
The average and (range) RNA yield of the leucocytes was 13
(2.3-28.8) 	g. On average 237 (79-353) mg muscle tissue was
sampled. Half of each sample was analysed for RNA quantity,
yielding on average 16.9 (4.1-41.8) 	g RNA. From the average 197
(61-430) mg adipose tissue 3.9 (1.4-8.5) 	g RNA could be obtained.
RNA from all samples was of good quality. Gene-expression profil-
ing with the material showed significant associations between anthro-
pometric variables and genes involved in glucose homeostasis. Thus,
tissue sampling in human is feasible and can be used for gene-
expression profiling clinical pharmacology studies.
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CYP GENOTYPES INFLUENCE THE EFFECT OF TAMOX-
IFEN THERAPY ON SERUM LIPIDS. M. I. Rehman, MD, K. Lee,
MD, PhD, A. Bermes, BSc, T. Skaar, PhD, M. Arefayene, L. Li, PhD,
V. Stearns, MD, D. F. Hayes, MD, D. A. Flockhart, MD, PhD,
Indiana University School of Medicine, Sungkyunkwan University
School of Medicine, Johns Hopkins University, University of Mich-
igan, Indianapolis, IN.
Beneficial effects of tamoxifen therapy on LDL-cholesterol have
been reported in several studies. We examined the relationship be-
tween genetic polymorphisms in CYP2D6 (*1, *4, *5, *6 and *10)
and CYP2C9 (*1, *2 and *3) genes and serum lipid profile in 28
women who took tamoxifen (20mg/day) for the management of
breast cancer. The fasting serum lipid profiles were evaluated before
starting tamoxifen therapy and at the end of four months of treatment.
The total and LDL-cholesterol lowering effect of tamoxifen was not
significantly different among groups carrying different CYP2D6 ge-
notype variants. The same was true for CYP2C9 groups. A significant
decrease in total and LDL-cholesterol was noted in women who
carried a combination of *1/*1 variants of CYP2D6 and CYP2C9
genes or a combination including *1/*1of either CYP combined with
any other variant of the other CYP (p0.0003 and 0.0001 for total
and LDL cholesterol respectively). CYP2D6 *1/*10 combined with a
heterozygous variant of CYP2C9 did not adversely influence the
beneficial effect of tamoxifen consistent with the *10 variant only
partially decreasing enzyme activity. No beneficial effect of tamox-
ifen was seen in the group of patients who carried variants of both
CYPs. The use of new multi-comparison algorithms to evaluate the
effects of multiple genetic variants on robust measures of drug
response is critical to the demonstration of predictive pharmacoge-
netic patterns.
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